Phentolamine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "Alpha" to "α") |
Neil.m.young (talk | contribs) (Text replacement - "α 1" to "α<sub>1</sub>") |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[α 1 Blocker]]; Antidote, Extravasation; [[Antihypertensive]] | *Type: [[α<sub>1</sub> Blocker]]; Antidote, Extravasation; [[Antihypertensive]] | ||
*Routes of Administration: IV, IM | *Routes of Administration: IV, IM | ||
*Common Trade Names: OraVerse | *Common Trade Names: OraVerse | ||
Revision as of 02:21, 18 August 2017
Administration
- Type: [[α1 Blocker]]; Antidote, Extravasation; Antihypertensive
- Routes of Administration: IV, IM
- Common Trade Names: OraVerse
Adult Dosing
- Pheochromocytomectomy adjunct: 5mg IM/IV q2-4h PRN
- Start: 1-2h preop
- Extravasation (norepinephrine-associated): 5-10mg injected into affected area x1
- Start: within 12h of extravasation
- Hypertensive crisis: 5mg IM/IV q2-4h PRN
Pediatric Dosing
- Pheochromocytomectomy adjunct: 1mg IM/IV q2-4h PRN
- Start: 1-2h preop
Special Populations
- Pregnancy Risk Factor: C
Renal Dosing
- No dosing adjustments
Hepatic Dosing
- No dosing adjustments
Contraindications
Adverse Reactions
Serious
- MI
- stroke
- hypotension, severe
- arrhythmias
- PUD
- priapism
Common
- tachycardia
- weakness
- dizziness
- flushing
- orthostatic hypotension
- nasal congestion
- nausea
- vomiting
- diarrhea
Pharmacology
- Half-life: 19 minutes
- Metabolism: Urine
- Excretion: CYP450
Mechanism of Action
References
<Epocrates, UpToDate>